Camber FDA Thursday, May 11, 2023 0.00 Neutral

FDA Approves LENALIDOMIDE — Camber Pharmaceuticals, Inc.

Camber Pharmaceuticals, Inc. announced the FDA’s approval of its ANDA for oral Lenalidomide, granting the company a license to market a generic version of the drug and intensifying competitive dynamics within the market.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day